<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>283</serviceExecutionTime><Trial id="254696"><TitleDisplay>Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients</TitleDisplay><TitleOfficial>Prospective Evaluation of Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients Undergoing Invasive ICP Monitoring</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02695264</Identifier><Identifier type="Organisational Study">HS-028</Identifier></Identifiers><Indications><Indication id="1860">Intracranial hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Disease marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Disease marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="3254" role="Disease marker" type="Physiological">Intracranial pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>HeadSense-1000 (HS-1000) system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1040560" type="Company"><TargetEntity id="4298210588" type="organizationId">Children's Hospital Medical Center Of Akron</TargetEntity></SourceEntity><SourceEntity id="1069294" type="Company"><TargetEntity id="5037431858" type="organizationId">Headsense Medical Ltd</TargetEntity></SourceEntity><SourceEntity id="1860" type="ciIndication"><TargetEntity id="D019586" type="MeSH"></TargetEntity><TargetEntity id="-700672172" type="omicsDisease"></TargetEntity><TargetEntity id="2753" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1069294">HeadSense Medical Ltd</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1040560">Akron Children's Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateStart>2016-08-31T00:00:00Z</DateStart><DateEnd type="actual">2016-12-26T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:39:35Z</DateChangeLast><DateAdded>2016-03-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Akron Children's Hospital</Affiliation><Name>Michael L Forbes, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Males and females&amp;lt;/= 18 years old admitted to the PICU whose treatment includes a surgical ICP monitor&lt;/li&gt;&lt;li&gt;Subject or legal authorized representative (per local regulation) is able and willing to comply with the requirements of the protocol&lt;/li&gt;&lt;li&gt;Subject or legal authorized representative (per local regulation) is able to understand and sign written informed consent to participate in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject with an invasive ICP monitor placed 10 days or before the date of recording for EVD monitor or 5 days or before the date of recording for Bolt monitor&lt;/li&gt;&lt;li&gt;Subjects with more than one invasive ICP monitor in place at the time of recording&lt;/li&gt;&lt;li&gt;Ear disease/ear trauma&lt;/li&gt;&lt;li&gt;Subjects with severe head trauma in which the location and/or severity of the skull fracture(s), ie, frank skull fracture or major joint dislocations with parenchyma exposed to room pressure, may jeopardize HeadSense monitoring procedure (Post-craniotomy patients with intact dura and accurate ICP values from the invasive EVD are eligible)&lt;/li&gt;&lt;li&gt;Severe TBI that jeopardizes HS-1000 monitoring procedure&lt;/li&gt;&lt;li&gt;Cerebral spinal fluid (CSF) otorrhea&lt;/li&gt;&lt;li&gt;Allergy/hypersensitivity to test materials&lt;/li&gt;&lt;li&gt;Pregnant or breast feeding&lt;/li&gt;&lt;li&gt;Current enrollment (or within 30 days) in another investigational device or drug study, or receiving an investigational agent&lt;/li&gt;&lt;li&gt;Any condition that jeopardizes study participation (abnormal clinical/lab finding)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>ICP recordings from the HS-1000 device compared to those from the invasive ICP monitor</Description><Timeframe>5 days of bolt insertion or 10 days of EVD insertion</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety of the HS-1000 as determined by number of reported device-related adverse events</Description><Timeframe>Up to 48 h after last recording</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to prospectively evaluate the accuracy and safety of      non-invasive intracranial pressure (ICP) measurements using the HeadSense-1000 (HS-1000)      device compared to the current invasive external ventricular device (EVD) or parenchymal      (bolt) monitoring devices in the pediatric population.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a  pilot study conducted at Akron Children's Hospital. A maximum of 40 patients      with severe traumatic brain injury (TBI) or neurological conditions requiring ICP monitoring      would be studied over two years. All patients treated with either surgical ICP monitor      (external ventricular drain [EVD] or subarachnoid manometer [Bolt]) are eligible for study      enrollment. The HS-1000 device would be deployed as soon as possible after surgical ICP      monitor placement to record and collect data in parallel with the surgical device.&lt;/para&gt;&lt;para&gt;To assess the accuracy and safety of the HS-1000 device as an alternative to the invasive      ICP procedure, the investigators would compare ICP readings obtained by the HS-1000      monitoring system to measurements recorded by the surgical device during 15 to 30 min      recording sessions.&lt;/para&gt;&lt;para&gt;ICP readings would be recorded from both the invasive and HeadSense non-invasive ICP monitor      for an aggregate of 30 min. During the recording sessions, a webcam would take periodic      snapshots of the ICP monitor and/or bedside monitor picturing the ICP values and other      clinical parameters that are displayed on screen, with a focus on blood pressure and heart      rate (HR). Recording sessions would be done until an aggregate of at least 30 min of data      are collected, depending on the patient's clinical condition. Recording sessions may be      repeated over several days until the 30 min target was reached.&lt;/para&gt;&lt;para&gt;The HeadSense headset would be removed between recordings. Recording should be done only in case      the patient's clinical condition allows it (ie, patient is in supine position and does not      require any clinical intervention or treatment at the time of the recording). In case the      patient requires some clinical intervention the recording would be stopped and would be      resumed only after the intervention was done and the patient's clinical condition allows      resuming of the recording.&lt;/para&gt;&lt;para&gt;Lastly, the investigators would also place a commercial sound meter in the patient's room      to collect baseline data on exposure to ambient noise within the Pediatric Intensive Care      Unit (PICU) treatment environment. This data would facilitate a device-versus-ambient sound      comparison, a component of the device safety profile.&lt;/para&gt;&lt;para&gt;Study patient demographics would be collected to include patient medical record number, age,      gender, diagnosis, medical information, and the patient's clinical course pertinent to the      ICP monitoring until the attending physician determines invasive ICP measurement was no      longer necessary. Additional demographic, diagnostic parameters, severity of illness      calculations, and procedures would be obtained from the Virtual Pediatric Systems (VPS, LLC)      Pediatric Intensive Care Unit clinical outcomes database. The patient would be followed for      48 h post ICU discharge for any adverse events.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial was withdrawn as the Clinical Trial Agreement not executed.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Akron Children's Hospital</Name><Address1>Akron</Address1><Address2>Ohio</Address2><Address3>44308</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15969">Subjects with Traumatic Brain Injury</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02695264</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="43051"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="43218"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="42924"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Other neurological disease" id="43054">Assessment of serious/treatment emergent adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="34308"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32748">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24024"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24094"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24096">Subjects participating in any investigational drug/device study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="24155"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24963"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24095">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-02-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-03-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-12-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="258771"><TitleDisplay>Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder</TitleDisplay><TitleOfficial>Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02745301</Identifier><Identifier type="Organisational Study">151565</Identifier></Identifiers><Indications><Indication id="1771">Transitional cell carcinoma</Indication><Indication id="2380">Bladder cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="9" role="Disease marker" type="Genomic;Proteomic">Cellular tumor antigen p53</BiomarkerName><BiomarkerName id="58" role="Disease marker" type="Genomic;Proteomic">Telomerase reverse transcriptase</BiomarkerName><BiomarkerName id="85" role="Disease marker" type="Genomic;Proteomic">Fibroblast growth factor receptor 3</BiomarkerName><BiomarkerName id="92" role="Disease marker" type="Genomic;Proteomic">Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform</BiomarkerName><BiomarkerName id="102" role="Disease marker" type="Genomic;Proteomic">Cyclin-dependent kinase inhibitor 2A</BiomarkerName><BiomarkerName id="401" role="Disease marker" type="Genomic;Proteomic">Twist-related protein 1</BiomarkerName><BiomarkerName id="488" role="Disease marker" type="Genomic;Proteomic">Cystatin B</BiomarkerName><BiomarkerName id="5309" role="Disease marker" type="Genomic">One cut domain family member 2</BiomarkerName><BiomarkerName id="6801" role="Disease marker" type="Genomic">Homeobox protein OTX1</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1149572" type="Company"><TargetEntity id="5056405740" type="organizationId">Element Diagnostics LLC</TargetEntity></SourceEntity><SourceEntity id="20693" type="Company"><TargetEntity id="4296216897" type="organizationId">Vanderbilt University</TargetEntity></SourceEntity><SourceEntity id="1771" type="ciIndication"><TargetEntity id="10044412" type="MEDDRA"></TargetEntity><TargetEntity id="D002295" type="MeSH"></TargetEntity><TargetEntity id="-807613677" type="omicsDisease"></TargetEntity><TargetEntity id="677" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2380" type="ciIndication"><TargetEntity id="C67" type="ICD10"></TargetEntity><TargetEntity id="188.9" type="ICD9"></TargetEntity><TargetEntity id="10005003" type="MEDDRA"></TargetEntity><TargetEntity id="-2101107804" type="omicsDisease"></TargetEntity><TargetEntity id="578" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20693">Vanderbilt University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1149572">Element Diagnostics</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2016-04-30T00:00:00Z</DateStart><DateEnd type="estimated">2020-09-30T00:00:00Z</DateEnd><DateChangeLast>2017-06-16T09:19:03Z</DateChangeLast><DateAdded>2016-04-25T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>pamela.steele@vanderbilt.edu</Email><Name>Pamela Steele, RN</Name></Contact><Contact type="Scientific contact"><Affiliation>Vanderbilt University</Affiliation><Name>Kristen R Scarpato, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Suspected or confirmed urothelial type bladder cancer&lt;/li&gt;&lt;li&gt;Scheduled for a transurethral resection of bladder tumor (TURBT) or cystectomy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt; 18 years of age&lt;/li&gt;&lt;li&gt;Known concurrent upper urinary tract disease&lt;/li&gt;&lt;li&gt;History of bladder or prostate radiation&lt;/li&gt;&lt;li&gt;Patients who are unwilling or unable to give consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in urinary biomarker value from baseline following removal of bladder tumor: urinary biomarkers will be assessed pre-operatively from voided specimens. 1 month post-operatively, voided urine will again be assessed for changes in the level of urinary biomarker. DNA will be isolated from tissue or urine using commercially available validated kits. DNA will be quantified by standard procedures and analyzed for somatic mutation by targeted resequencing of selected regions of the genome. Specific gene targets include TP53, FGFR3, CDKN2A, TERT, and PIK3CA. Hypermethylation analysis will be conducted by bisulfite conversion of isolated DNA and sequencing to determine degree of methylation of specific CpG islands. CpG islands located in the promoter regions of OTX1, TWIST1 and ONECUT2 will be analyzed. Levels of Cystatin B will be assessed by quantitative immunoassay directly from urine</Description><Timeframe>An average of 1 month after surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in urinary biomarker value throughout the day: 5 patients will provide and additional 2 pre-operative urine specimens (for a total of 3 preoperative specimens) from a single day to assess for any potential time-dependent variation. Each specimen must be collected at least 4 h apart. These 5 patients will be asked to collect a 'morning', 'midday' and 'evening' urine specimen</Description><Timeframe>1 day</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is  to assess the persistence of bladder cancer-specific biomarkers in urine collected      pre-operatively, in resected cancer tissue and in urine collected post-operatively. A panel      of sensitive and specific bladder cancer biomarkers will be used to establish a signature of      disease in pre-operative patients with a positive diagnosis for bladder cancer by current      standard of care (eg, in-office cystoscopy, or cystoscopy). The specificity of these      markers will be assessed, as well as the degree of non-specific signal attributable to other      sources of biomolecules, by analyzing resected tumor tissue for the same biomarkers.      Finally, post-operative urine will be assessed for the presence of these markers. To the      extent this biomarker panel can be determined to be specific and sensitive, it may serve as      an indicator of the degree to which the surgical intervention successfully eradicated the      underlying disease. The investigators also aim to assess the stability of a biomarker      signature in urine but evaluating several patient specimens over various time points      throughout the day.&lt;/para&gt;&lt;para&gt;Hypothesis: &lt;br/&gt;Bladder cancer biomarkers will be elevated in preoperative and intraoperative      urine specimens with direct correlation to the intact lesion(s), but will diminish      significantly or disappear in urine specimens post-operatively with as a function of      completion of resection. Further, the persistence of disease-specific biomarkers in urine      post-operatively may correlate with the risk of recurrence or progression.&lt;br/&gt;Biomarker levels will be determined from pre-, intra- and post-operative urine specimens, as      well as from resected bladder tissue and will be statistically compared for changes that      correlate with presence or absence of visible disease. Biomarkers from tissue samples will      be quantified and compared with urine sample values.&lt;/para&gt;&lt;para&gt;The specific aims of the current proposal will be:&lt;br/&gt;To assess the stability of a biomarker signature in urine. To date, efforts across the      biomarker field have relied on the detection of cancer in the context of a single patient      specimen collected at a single point in time. The consistency of the biomarker signature      across specimens provided by the same patient has not been fully described. The current      study will assess the consistency with which the biomarkers composing the panel can be      detected across urine specimens collected at multiple points in time in a subset of      patients. This data will inform the utility of single point-in-time collection with regard      to accurately defining the disease signature.&lt;br/&gt;To assess the persistence of bladder cancer-specific biomarkers in urine collected      pre-operatively, in resected cancer tissue, and in urine collected post-operatively. A panel      of sensitive and specific bladder cancer biomarkers will be used to establish a signature of      disease in pre-operative patients with a positive diagnosis for bladder cancer by current      standard of care (eg, in-office cystoscopy). The specificity of these markers will be      assessed, as well as the degree of non-specific signal attributable to other sources of      biomolecules, by analyzing resected tumor tissue for the same biomarkers. Finally,      post-operative urine will be assessed for the presence of these markers. To the extent this      biomarker panel can be determined to be specific and sensitive, it may serve as an indicator      of the degree to which the surgical intervention successfully eradicated the underlying      disease.&lt;br/&gt;To determine whether persistence of biomarkers in patient urine post-operatively      correlates with recurrence or progression. The same panel of markers detected in the      pre-operative urine and tumor will be assayed in voided urine collected during routine      follow-up surveillance visits for a period of one year. Biomarkers will be monitored for      persistence and quantitative change in levels.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study consents and enrolls 50 patients with a diagnosis of primary or recurrent bladder cancer by cystoscopy that requires transurethral resection of the bladder tumor (TURBT) or radical cystectomy (RC). Patients will be identified for participation if known to have bladder cancer and have recurrent tumor on office cystoscopy, or will present for a new hematuria work up and have evidence of transitional cell carcinoma (TCC) on office cystoscopy. Patients with transitional cell carcinoma of the bladder will be observed for urinary biomarkers.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>The Vanderbilt Clinic, VUMC</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37232</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>pamela.steele@vanderbilt.edu</Email><Name>Pamela Steele, RN, BSN</Name><Phone>615-343-2120</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Bladder cancer</Disease><PatientSegments><PatientSegment><PatientSegment id="7815">Subjects with Resectable Bladder Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11954">Subjects with Urothelial cell/Transitional Cell Bladder Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02745301</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bladder cancer" id="11769"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Bladder cancer" id="11782"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Bladder cancer" id="11795"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Bladder cancer" id="11769"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bladder cancer" id="11795"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bladder cancer" id="11799"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Bladder cancer" id="11789"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></OtherEndpoint><OtherEndpoint disease="Bladder cancer" id="11793"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bladder cancer" id="7449"><Criterion>Subjects with Resectable Bladder Cancer</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7472"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="7478">Subjects with history of/scheduled for surgery/procedure for bladder cancer</SubCriterion><SubCriterion disease="Bladder cancer" id="12898">Subjects with history of/scheduled for transurethral resection (TUR)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bladder cancer" id="7491"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="22362"><Criterion>Subjects with Urothelial Cell/Transitional Cell Bladder Cancer</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bladder cancer" id="9003"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Bladder cancer" id="9030"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="9035">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bladder cancer" id="25448"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="9048">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bladder cancer" id="27777"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="9049">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-09-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-04-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-06-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="274120"><TitleDisplay>Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes</TitleDisplay><TitleOfficial>Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01724580</Identifier><Identifier type="Organisational Study">14559</Identifier><Identifier type="Secondary Organisational">I4V-MC-JAGA</Identifier><Identifier type="Other">2015-003424-31</Identifier><Identifier type="Trial Acronym">JAGA</Identifier></Identifiers><Indications><Indication id="2475">Dermatomyositis</Indication><Indication id="3600">Autoinflammatory disease</Indication><Indication id="742">Vascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1005" role="Therapeutic effect marker" type="Genomic;Proteomic">C-X-C motif chemokine 10</BiomarkerName><BiomarkerName id="1849" role="Therapeutic effect marker" type="Genomic;Proteomic">Signal transducer and activator of transcription 1-alpha/beta</BiomarkerName><BiomarkerName id="3374" role="Therapeutic effect marker" type="Physiological">Bone mineral density</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="26971" role="Therapeutic effect marker" type="Genomic;Proteomic">Interferons</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>baricitinib</Name><Drug id="59098">baricitinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59098">baricitinib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59098" type="Drug"><TargetEntity id="472088" type="siDrug">Baricitinib</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="2475" type="ciIndication"><TargetEntity id="M33" type="ICD10"></TargetEntity><TargetEntity id="10012503" type="MEDDRA"></TargetEntity><TargetEntity id="D003882" type="MeSH"></TargetEntity><TargetEntity id="221" type="ORPHANET"></TargetEntity><TargetEntity id="-990050583" type="omicsDisease"></TargetEntity><TargetEntity id="139" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="742" type="ciIndication"><TargetEntity id="10059245" type="MEDDRA"></TargetEntity><TargetEntity id="D014652" type="MeSH"></TargetEntity><TargetEntity id="-90096021" type="omicsDisease"></TargetEntity><TargetEntity id="3754" type="siCondition"></TargetEntity><TargetEntity id="1157" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3562" type="Action"><TargetEntity id="1506" type="Mechanism">Jak1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3564" type="Action"><TargetEntity id="1505" type="Mechanism">Jak2 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3562">Jak1 tyrosine kinase inhibitor</Action><Action id="3564">Jak2 tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><PatientCountEvaluable>18</PatientCountEvaluable><DateChangeLast>2019-02-22T10:03:32Z</DateChangeLast><DateAdded>2016-10-24T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Eli Lilly and Company</Affiliation><Name>Eli Lilly and Company</Name></Contact><Contact type="Public contact"><Affiliation>Eli Lilly</Affiliation><Email>EU_Lilly_Clinical_Trials@lilly.com</Email><Name>Clinical Trial Registry Office</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Are &gt;/= 17.5 months of age (or are ≥6 months of age with Aicardi-Goutières Syndrome [AGS]). Participants&amp;lt; 17.5 months of age can be considered for enrollment after discussion with the sponso&lt;/li&gt;&lt;li&gt;Have systemic signs and symptoms of inflammation as manifested by the presence of two or more of the following symptoms: rash, fever, musculoskeletal pain, headache, fatigue, weakness, respiratory/breathing symptoms, or ulcers/ischemic lesions&lt;/li&gt;&lt;li&gt;Have an average daily Diary Score of &gt;/= 0.5 (CANDLE Diary; used also for CANDLE-related conditions, AGS Diary) or &gt;/= 1.0 (SAVI) or &gt;/= 1.0 exclusive of headache and fever symptoms (JDM Diary) assessed over at least 2 weeks prior to entry, if available. Otherwise, participants can complete the diary after study consent is signed during the screening period and meet the inclusion criteria for enrollment into the study&lt;/li&gt;&lt;li&gt;Are &gt;/= 8.5 kg in body weight. Patients weighing&amp;lt; 8.5 kg can be considered for enrollment after discussion with the sponsor&lt;/li&gt;&lt;li&gt;Have been previously treated with at least one biological therapy and, in the opinion of the investigator, did not respond or are no longer responding to therapy. If the patient has been diagnosed with CANDLE, Nakajo-Nishimura Syndrome (NNS), SAVI, AGS or an equivalent syndrome, the need for previous biological therapy is not required&lt;/li&gt;&lt;li&gt;Require treatment with oral corticosteroids (&gt;/= 0.15 mg/kg/day] of prednisone or its equivalent) for control of systemic signs and symptoms of their chronic inflammatory disease for at least 2 weeks prior to study entry, or in the opinion of the investigator, have failed an adequate course of steroids. Treatment with or  failure of treatment  with  steroids is not required  forparticipants with AGS or a confirmed genetic diagnosis of CANDLE or SAVI&lt;/li&gt;&lt;li&gt;Have had previous documented elevations in acute-phase reactants (for eg, high sensitivity C-reactive protein) considered to be the result of the inflammatory disease (patients with CANDLE or CANDLE-related conditions only)&lt;/li&gt;&lt;li&gt;Have the ability to provide informed consent or have legal representative who is willing and able to provide written informed consent, provided that assent is obtained from patients at an age-appropriate level&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have received an immunosuppressive biological agent/monoclonal antibody within four half-lives prior to entry, for eg, anakinra (4 half-lives = 18 h); etanercept (4 half-lives = 18 days); infliximab; adalimumab (4 half-lives = 36 days); use of intravenous immune globulin (IVIg) is permitted&lt;/li&gt;&lt;li&gt;Are pregnant or nursing at the time of entry&lt;/li&gt;&lt;li&gt;Are females of childbearing potential (women &gt; 12 or who have had at least one menstrual period regardless of age) who are sexually active and who do not agree to use two forms of highly effective methods of birth control or remain abstinent during the study and for at least 28 days following the last dose of investigational product&lt;/li&gt;&lt;li&gt;Are sexually active males who do not agree to use two forms of highly effective birth control with female partners of childbearing potential or remain abstinent during the study and for at least 28 days following the last dose of investigational product&lt;/li&gt;&lt;li&gt;Have had symptomatic herpes zoster infection within 12 weeks prior to entry or during the screening period&lt;/li&gt;&lt;li&gt;Have a history of disseminated/complicated herpes zoster (for eg, multidermatomal involvement, ophthalmic zoster, central nervous system [CNS] involvement, postherpetic neuralgia)&lt;/li&gt;&lt;li&gt;Have evidence of active infection, at the time of entry or during the screening period, that in the opinion of the investigator, would pose an unacceptable risk for participating in the study&lt;/li&gt;&lt;li&gt;Have a history of active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV)&lt;/li&gt;&lt;li&gt;Have documented high titer autoantibodies suggestive clinically of autoimmune diseases other than severe JDM&lt;/li&gt;&lt;li&gt;Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study&lt;/li&gt;&lt;li&gt;Have had a serious systemic or local infection (including an infectious mononucleosis-like illness or herpes zoster) within 12 weeks prior to entry or during the screening period&lt;/li&gt;&lt;li&gt;Have been exposed to a live vaccine within 12 weeks prior to entry or are expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study&lt;/li&gt;&lt;li&gt;Note: Investigators should review the vaccination status of the patients and follow the local guidelines for vaccination with non-live vaccines intended to prevent infectious disease prior to entering patients into the study&lt;/li&gt;&lt;li&gt;Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB&lt;/li&gt;&lt;li&gt;Have a serious and/or unstable illness that, in the opinion of the investigator, poses an unacceptable risk for the patients participation in the study&lt;/li&gt;&lt;li&gt;Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of&amp;lt; 40 ml/min/1.73m2&lt;/li&gt;&lt;li&gt;Have or have had a history of lymphoproliferative disease; or signs or symptoms suggestive of possible lymphoproliferative disease, or active primary or recurrent malignant disease; or been in remission from clinically significant malignancy for&amp;lt; 5 years Note: patients with resolved cervical dysplasia, or no more than three successfully treated basal-cell carcinoma of the skin, may participate in this study&lt;/li&gt;&lt;li&gt;Have a history of chronic alcohol abuse or intravenous (IV) drug abuse within the two years prior to entry&lt;/li&gt;&lt;li&gt;Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures&lt;/li&gt;&lt;li&gt;Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>AGS diary: reduction in mean daily score to &lt; 0.5</Description><Timeframe>End of study (date of regulatory approval of this compound for any indication in any country)</Timeframe></Measure><Measure><Description>SAVI diary: reduction in mean daily score, exclusive of respiratory/breathing symptoms, to &lt;1.0 and respiratory/breathing symptoms score a &lt;1.0 increase from baseline</Description><Timeframe>End of study (date of regulatory approval of this compound for any indication in any country)</Timeframe></Measure><Measure><Description>DM diary: reduction in mean score by 1 point in at least 3 categories</Description><Timeframe>End of study (date of regulatory approval of this compound for any indication in any country)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy: reduction in mean Autoinflammatory Diary Scores (ADS) to &lt; 0.5</Description></Measure><Measure><Description>Efficacy: reduction of steroid doses by at least 50% or 0.15 mg/kg/day in patients receiving steroids at baseline</Description></Measure><Measure><Description>Vital signs, safety and adverse events (AEs)</Description><Timeframe>At each visit</Timeframe></Measure><Measure><Description>Quality of life</Description></Measure><Measure><Description>Organ inflammation</Description></Measure><Measure><Description>Changes in IFN-induced biomarkers</Description></Measure><Measure><Description>CANDLE, CANDLE-related, SAVI patients receiving steroids: decrease in the daily dose of corticosteroids (systemic corticosteroids &lt; 0.15 mg/kg/day oral prednisone or a decrease of at least 50% of the patient’s daily dose at baseline)</Description><Timeframe>End of study (date of regulatory approval of this compound for any indication in any country)</Timeframe></Measure><Measure><Description>JDM patients receiving steroids: decrease in the daily dose of corticosteroids (systemic corticosteroids &lt; 0.2 mg/kg/day oral prednisone or a decrease of at least 25% of the patient’s daily dose at baseline)</Description><Timeframe>End of study (date of regulatory approval of this compound for any indication in any country)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2016, results were presented. A total of seven patients reported atleast one serious AE with infection being the most common one. Avascular necrosis, BK viremia and azotemia were the serious AEs which caused study discontinuation whereas neutropenia caused temporary interruption of baricitinib. Upper respiratory infections, gastroenteritis, cough and BK viruria and viremia  were the most common AEs reported. One patient died due to worsening interstitial lung disease with development of respiratory failure following 4 months after baricitinib discontinuation and initiation of another JAK inhibitor [&lt;ulink linkType="Reference" linkID="1767878"&gt;1767878&lt;/ulink&gt;]. Similar results were published in July 2018 [&lt;ulink linkType="Reference" linkID="2074168"&gt;2074168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2018, results were published. Due to lack of efficacy and BK viremia and azotemia, treatment discontinuation was noted in three patients  (two patients with genetically undefined conditions and one patient with CANDLE, respectively) [&lt;ulink linkType="Reference" linkID="2074168"&gt;2074168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to evaluate JAK 1/2  inhibitors in treatment of conditions like Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), CANDLE-related conditions, Severe Juvenile dermatomyositis (JDM), Stimulator of interferon genes (STING)-associated vasculopathy with onset during infancy (SAVI).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2016, results were presented. Mean percentage reduction (last visit versus baseline) in ADS was 85% (p = 0.001; 9 of 11 patients achieved ADS of &amp;lt; 0.5) and in prednisone dose was 75% (p = 0.004; 8 of 11 patients achieved reduction in steroid doses from baseline of &amp;gt; 50%). A total of four patients discontinued prednisone completely. Mean dose of baricitinib was 6.9 mg/day at the last patient visit [&lt;ulink linkType="Reference" linkID="1767878"&gt;1767878&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were presented in November 2017. Weight and renal function significantly influenced pharmacokinetics parameters volume of distribution and clearance, respectively. The half-life of baricitinib, particularly in patients less than or equal to 40 kg, was considerably shorter than in adult rheumatoid arthritis patients, resulted in the need for dosing up to 4 times daily. IFN-alpha stimulated STAT-1 phosphorylation (pSTAT-1) in immune cells from Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature (CANDLE) and STING Associated Vasculopathy with onset during infancy negatively correlated with plasma baricitinib levels. With increased drug exposure, 25-gene IFN score and serum IP-10 levels, both markers of IFN signaling were significantly decreased. A subset of CANDLE patients normalized the 25-gene IFN score at AUC24,ss values between 1500 to 2000 nM*h, but higher exposures were required in patients with more severe disease [&lt;ulink linkType="Reference" linkID="1978193"&gt;1978193&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2018, results were published. There was a decrease in the median daily symptom score from 1.3 (p &amp;lt; 0.0001). Daily prednisone doses decreased from 0.44 to 0.11 mg/kg/day (p &amp;lt; 0.01) in 14 patients receiving corticosteroids at baseline, and 5/10 patients with CANDLE achieved lasting clinical remission. There was a significant improvement in patients quality of life and height and bone mineral density Z-scores, and the IFN biomarkers were found to decrease [&lt;ulink linkType="Reference" linkID="2074168"&gt;2074168&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive oral &lt;ulink linkType="Drug" linkID="59098"&gt;baricitinib&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received baricitinib. Unresponsive or partially responsive patients received escalated doses of baricitinib [&lt;ulink linkType="Reference" linkID="1767878"&gt;1767878&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2074168"&gt;2074168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients received baricitinib (between 0.1 to 17 mg, qd) for up to 53 months [&lt;ulink linkType="Reference" linkID="1978193"&gt;1978193&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>baricitinib</Name><Drug id="59098">baricitinib</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="2195">Gastroenteritis</Indication></AdverseEvent><AdverseEvent><Indication id="3499">BK virus infection</Indication></AdverseEvent><AdverseEvent><Indication id="516">Upper respiratory tract infection</Indication></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication></AdverseEvent><AdverseEvent><Indication id="82">Cough</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="638956">baricitinib</Intervention><Treatments><Treatment><Dose>0.1 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>17 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Great Ormond Street Hospital</Name><Address1>London</Address1><Address2>England</Address2><Address3>WC1N 1EH</Address3><CountrySubDivision>England</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Great Ormond Street Hospital</Name><Address1>London</Address1><Address3>WC1N 1EH</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Children's Hospital of Philadelphia</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Translational Autoinflammatory Disease (TADS)</Name><Address1>Bethesda</Address1><Address2>Maryland</Address2><Address3>20892</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Children's Hospital of Philadelphia</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Translational Autoinflammatory Disease (TADS)</Name><Address1>Bethesda</Address1><Address2>Maryland</Address2><Address3>20892</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other dermatological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17864">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15964">Subjects with Dermatomyositis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01724580</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2015-003424-31</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Other dermatological disease" id="42862"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Other dermatological disease" id="43231"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Other dermatological disease" id="43234"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Other dermatological disease" id="43653"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other dermatological disease" id="32830"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="34310"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="33091">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other dermatological disease" id="23963"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24587">Subjects with autoimmune diseases/disorders</SubCriterion><SubCriterion disease="Other dermatological disease" id="24588">Subjects with systemic/generalized bacterial/viral/fungal infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="24365"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24369">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="24773"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="24956"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24367">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="26749"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24354">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateFirstReceived>2012-11-05T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-10-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-09-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="Added"><Date>2018-09-24T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change></ChangeHistory></Trial><Trial id="287106"><TitleDisplay>Intermittent Hypoxia and Inspiratory Threshold Loading to Enhance Inspiratory Muscle Function</TitleDisplay><TitleOfficial>Intermittent Hypoxia and Inspiratory Threshold Loading as Strategies to Enhance Inspiratory Muscle Function</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03029559</Identifier><Identifier type="Organisational Study">IRB201601878</Identifier></Identifiers><Indications><Indication id="1038">Muscle disease</Indication></Indications><BiomarkerNames><BiomarkerName id="330" role="Toxic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Toxic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="1913" role="Toxic effect marker" type="Physiological">Arterial oxygen saturation</BiomarkerName><BiomarkerName id="2052" role="Therapeutic effect marker" type="Physiological">Forced inspiratory flow</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="10169" role="Therapeutic effect marker" type="Physiological">Oxygen saturation</BiomarkerName><BiomarkerName id="12110" role="Therapeutic effect marker" type="Physiological">Maximal inspiratory mouth pressure</BiomarkerName><BiomarkerName id="17803" role="Therapeutic effect marker" type="Physiological">Mouth occlusion pressure at 0.1 second after the onset of inspiratory effort</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Power breathe device</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>inspiratory threshold loading</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>intermittent hypoxia therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20575" type="Company"><TargetEntity id="4296863617" type="organizationId">University of Florida</TargetEntity></SourceEntity><SourceEntity id="1038" type="ciIndication"><TargetEntity id="G71" type="ICD10"></TargetEntity><TargetEntity id="728" type="ICD9"></TargetEntity><TargetEntity id="10028300" type="MEDDRA"></TargetEntity><TargetEntity id="-1952423694" type="omicsDisease"></TargetEntity><TargetEntity id="3505" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20575">University of Florida</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2017-02-17T00:00:00Z</DateStart><DateEnd type="actual">2018-02-19T00:00:00Z</DateEnd><DateChangeLast>2019-06-21T02:10:18Z</DateChangeLast><DateAdded>2017-02-05T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Florida</Affiliation><Name>Daniel Martin, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participating in three or fewer musculoskeletal strength training sessions per week at an intensity equivalent to 7 to 10 on the Modified Borg's scale&lt;/li&gt;&lt;li&gt;Participating in three or fewer cardiovascular endurance training sessions per week at an intensity equivalent to 7 to 10 on the Modified Borg's scale&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of cardiovascular disease (hypertension, arrhythmias, coronary artery disease, congenital and valvar heart diseases)&lt;/li&gt;&lt;li&gt;Diagnosis of neuromuscular disease&lt;/li&gt;&lt;li&gt;Diagnosis of any neurological disease&lt;/li&gt;&lt;li&gt;Presence of concurrent medical illness including infection, fractures&lt;/li&gt;&lt;li&gt;Diagnosis of obstructive sleep apnea&lt;/li&gt;&lt;li&gt;Diagnosis of obstructive/restrictive lung disease&lt;/li&gt;&lt;li&gt;Diagnosis of exercise induced asthma&lt;/li&gt;&lt;li&gt;Forced expiratory volume at one second/forced vital capacity (FVC)&amp;lt; 80% and/or FVC &amp;lt; 80% of predicted value indicating airway obstruction&lt;/li&gt;&lt;li&gt;Subjects on prednisolone therapy or selective serotonin reuptake inhibitor (SSRI) therapy will be excluded from the study.&lt;/li&gt;&lt;li&gt;Diagnosis of epilepsy or history of seizures and attention deficit disorders&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Diabetes&lt;/li&gt;&lt;li&gt;History of coagulation disorders&lt;/li&gt;&lt;li&gt;History of chronic pain&lt;/li&gt;&lt;li&gt;Body mass index(BMI)&amp;gt; 35 kg/m2&lt;/li&gt;&lt;li&gt;Subjects on prescription medicines such as beta blockers and other drugs that are prescribed in any of the exclusionary disorders listed above&lt;/li&gt;&lt;li&gt;Any other factor that in the investigators' opinions would prevent response to training or create an unsafe condition for the subject&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximal inspiratory pressure will be measured across all groups: maximal inspiratory pressure (MIP) which is a measure of inspiratory muscle strength will be measured as the MIP recorded at the mouth by a pressure manometer. Subjects will be seated upright in a comfortable chair and the nose occluded with clips. After exhaling to residual volume (RV), subjects place their lips around the mouthpiece and inspire as forcefully as possible for at least 3 s. Repeated measurements will be taken, with a 1- to 2-min rest between trials, until three measurements are obtained within 5% variability. Of these three values, the best MIP will be recorded</Description><Timeframe>Change between 15, 30, and 60 min</Timeframe></Measure><Measure><Description>Ventilatory responses to inspiratory loading will be measured across all groups: subjects will be asked to breathe as forcefully as possible against a inspiratory load( 2 to 4 sets of five repetitions) of either 40% of their maximal inspiratory pressure (MIP) or at 41 cm H2O (lowest of the two as the maximum resistance offered by the device is 41 cm H2O) using a inspiratory muscle training (IMT) device. During this task, a respiratory monitor will be connected to the IMT device. Parameters such as the inspiratory flow, volume and pressure generated by the subjects while breathing against the load will be recorded. Imposed work of breathing (WOBi) will be calculated as a product of the pressure generated and the inspired tidal volume when breathing against a fixed load (40% MIP)</Description><Timeframe>Change between 15, 30, and 60 min</Timeframe></Measure><Measure><Description>Mouth occlusion pressure (P0.1) will be measured across all groups: to record P0.1, the subjects will breathe through a mouth piece connected to a two way respiratory valve in a closed circuit. As the subjects breathe through the circuit, the inspiratory valve will be manually occluded during the expiratory phase and the occlusion will be maintained till the end of next inspiration. Occlusion will be random in order to prevent the subjects from getting conscious about the occlusions. The circuit is connected to the respiratory monitor and the negative pressure recorded in the first 100 ms of the occluded breath will be recorded as the subject's P0.1. Three such recordings will be obtained and the highest pressure amongst the three trials will be considered for analysis</Description><Timeframe>Change between 15, 30, and 60 min</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Heart rate variability (HRV) will be measured across all groups: heart rate variability (HRV): HRV will be assessed to determine the autonomic response to intermittent hypoxia. HRV will be measured using a three lead ECG and HRV recording kit</Description><Timeframe>Change between 15, 30, and 60 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Rehabilitation approaches introduced a stimulus to a motor system, with the goal to enhance      motor function to patients. The investigators used a Latin square, repeated measures design to study the effects of intermittent hypoxia (IH) administered alone and in combination with inspiratory threshold loading on the above stated respiratory parameters would result in increased inspiratory muscle strength and      ventilation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Investigators would use a Latin square, repeated measures design which will consist of 12      subjects participating in four experimental conditions.There would be an interval of 1 week      between each of the four conditions, which would serve as a washout period.&lt;/para&gt;&lt;para&gt;The subjects would be randomized into four groups:&lt;br/&gt;Group 1: IH + ITL: subjects would be exposed to a session of intermittent hypoxia (IH) followed by five sets of Inspiratory threshold loading (ITL).  A single session of IH would last for 45 min and will consist of alternating phases of hypoxia (FiO2: 9 to 11%) and hyperoxia (FiO2: 22 to 38%). Each hypoxic interval would last for 2 min whereas the hyperoxic interval lasts for 1 min each (15, 2 min episodes of hypoxia and 15, 1 min episodes of hyperoxia). Subjects would undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe). ITL will be administered at an intensity of 80% of the subject's maximal inspiratory pressure (MIP). The subjects would be instructed to take ten deep, forceful breaths through the threshold device followed by at least 2 min of rest. The process would be repeated four more times for a total of five sets of ten breaths each.&lt;br/&gt;Group 2: Intermittent hypoxia (IH): subjects would only be exposed to a session of intermittent hypoxia. A single session of IH would last for 45 min and will consist of alternating phases of hypoxia (FiO2: 9 to 11%) and hyperoxia (FiO2: 22 to 38%). Each hypoxic interval would last for 2 min whereas the hyperoxic interval lasts for 1 min each (15, 2 min episodes of hypoxia and 15, 1 min episodes of hyperoxia).&lt;br/&gt;Group 3: Sham IH + ITL: sham intermittent hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-min session of sham IH (normoxia). This would consist of the subject breathing room air (FiO2 = 21%) through a four way valve connected to the hypoxicator. Exposure to normoxia would be followed by five sets of ITL. Subjects would undergo inspiratory threshold loading (ITL) using a commercially available Threshold IMT device (Power breathe). ITL would be administered at an intensity of 80% of the subject's maximal inspiratory pressure (MIP). The subjects would be instructed to take ten deep, forceful breaths through the threshold device followed by at least 2 min of rest. The process would be repeated four more times for a total of five sets of ten breaths each.&lt;br/&gt;Group 4: Sham IH: sham intermittent hypoxia subjects would be exposed to a single 45 min session of sham intermittent hypoxia alone. This will consist of breathing room air for 45 min through a hypoxicator.&lt;/para&gt;&lt;para&gt;At the end of each of the five sessions, the subjects would rest in a reclining chair for 15 min while their heart rate, blood pressure, oxygen saturation and breathing would be monitored. Subjects that have a blood systolic blood pressure &amp;gt; 140 or diastolic pressure &amp;gt; 90 or SPO2 &amp;lt; 92% will be asked to remain in the laboratory for 15 additional min and the vital signs will be repeated. If the blood pressure and/or peripheral capillary oxygen saturation (SPO2) remain outside of the criteria mentioned above, the subject would be instructed to seek assessment by their health provider and the incident will be reported to the Institutional Review Board. Subjects will also be asked to report any discomfort.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Florida</Name><Address1>Gainesville</Address1><Address2>Florida</Address2><Address3>32611</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other respiratory disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16687">Others</PatientSegment><SubSegments><SubSegment id="18750">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03029559</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other respiratory disease" id="43449"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other respiratory disease" id="43450"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other respiratory disease" id="43450"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other respiratory disease" id="43004"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other respiratory disease" id="32992"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other respiratory disease" id="34643"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other respiratory disease" id="32993">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other respiratory disease" id="24309"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24430"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24966"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other respiratory disease" id="24661">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-02-19T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-01-17T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-02-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-03-01T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-07-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="302409"><TitleDisplay>Radiation Impact on Thromboembolic Events</TitleDisplay><TitleOfficial>Radiation Therapy and Venous Thromboembolic Events</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02696447</Identifier><Identifier type="Organisational Study">2015-09</Identifier><Identifier type="Trial Acronym">RIT</Identifier></Identifiers><Indications><Indication id="725">Solid tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="183" role="Therapeutic effect marker" type="Proteomic">D-dimer</BiomarkerName><BiomarkerName id="10684" role="Therapeutic effect marker" type="Cellular">Blood cells</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>brachytherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>radiation therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1039393" type="Company"><TargetEntity id="5035525465" type="organizationId">Centre Hospitalier Universitaire</TargetEntity></SourceEntity><SourceEntity id="1049937" type="Company"><TargetEntity id="5001314967" type="organizationId">Institut de Cancerologie de Lorraine</TargetEntity></SourceEntity><SourceEntity id="1149934" type="Company"><TargetEntity id="5051613604" type="organizationId">Centre Hospitalier General De Roanne</TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1049937">Institut de Cancérologie de la Loire</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1039393">Centre Hospitalier Universitaire de Saint Etienne</Company><Company id="1149934">Centre Hospitalier de Roanne</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>450</PatientCountEnrollment><DateStart>2016-06-14T00:00:00Z</DateStart><DateEnd type="estimated">2019-11-30T00:00:00Z</DateEnd><DateChangeLast>2019-04-27T09:48:36Z</DateChangeLast><DateAdded>2017-06-23T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient with a solid cancer (all locations) treated with radiation therapy and / or brachytherapy as curative intent&lt;/li&gt;&lt;li&gt;To be 18&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient with metastatic cancer&lt;/li&gt;&lt;li&gt;Patients whose follow-up at 6 months is not possible&lt;/li&gt;&lt;li&gt;Patient receiving an anti-coagulative medication (curative doses)&lt;/li&gt;&lt;li&gt;Pregnant or breastfeeding women&lt;/li&gt;&lt;li&gt;Person under protection of justice or unable to give consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Venous Thromboembolism event: all venous thromboembolism, whether symptomatic or discovered incidentally, objectified (CT angiography, lung scintigraphy, venous Doppler) between J1 of radiation treatment, up to 6 months following discontinuation of radiation treatment</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>C-reactive protein</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Complete blood count</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Dosage of D-dimer</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Symptomatic VTE</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Time of occurrence of VTE</Description><Timeframe>6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the present study is to determine the frequency and to identify main risk factors      for venous thromboembolism of venous thromboembolic complications in a population of cancer      patients treated with a curative intent by ionizing radiation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent will be observed to identify main risk factors      for venous thromboembolism.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>CH de Roanne</Name><Address1>Roanne</Address1><Contacts></Contacts></Site><Site><Name>Institut de cancérologie Lucien Neuwirth</Name><Address1>Saint-Priest-en-Jarez</Address1><Address3>42270</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="8985">Radiotherapy Related Adverse Events</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02696447</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cancer supportive care" id="19366"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19369">Assessment by Computed tomography (CT)/ PET scans</SubEndpoint><SubEndpoint disease="Cancer supportive care" id="19370">Assessment by Scintigraphy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19397"><Endpoint>Assessment of Morbidity Rates</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19421"><Endpoint>Assessment of compliance/adherence</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cancer supportive care" id="19329"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19333">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19397"><Endpoint>Assessment of Morbidity Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19407"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="45141"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="45181"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cancer supportive care" id="13314"><Criterion>Radiotherapy Related Adverse Events</Criterion></Inclusion><Inclusion disease="Solid tumor" id="33912"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13125">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="10699"><Criterion>Subjects with Advanced/Metastatic Solid Tumors</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10739"><Criterion>Subjects with History of Other Non Anti-cancer Drugs/Agents</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10743"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10752">Vulnerable population</SubCriterion><SubCriterion disease="Solid tumor" id="10753">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="10916"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10918"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10934">Vulnerable population</SubCriterion><SubCriterion disease="Cancer supportive care" id="10935">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="25522"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10926">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="25667"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10744">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="27783"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10927">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="27960"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10745">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-12-24T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-04-25T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>34.39 Months</EnrollmentPeriod><EnrollmentRate>13.09 Patients/Month</EnrollmentRate><DateFirstReceived>2016-02-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="314351"><TitleDisplay>Development of Obesity and Bariatric Surgery</TitleDisplay><TitleOfficial>Impacts of Bariatric Surgery on Obesity in China</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03296605</Identifier><Identifier type="Organisational Study">AF/SC-08/02.0</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="808" role="Disease marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="12058" role="Disease marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Disease marker" type="Anthropomorphic">Body height</BiomarkerName><BiomarkerName id="36136" role="Disease marker" type="Genomic;Proteomic">Cytokines</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1057007" type="Company"><TargetEntity id="5035551100" type="organizationId">Nanjing Drum Tower Hospital</TargetEntity></SourceEntity><SourceEntity id="1076098" type="Company"><TargetEntity id="5037969742" type="organizationId">Medical School of Nanjing University</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1057007">Nanjing Drum Tower Hospital</Company><Company id="1076098">Nanjing University Medical School</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2017-03-01T00:00:00Z</DateStart><DateEnd type="estimated">2025-03-30T00:00:00Z</DateEnd><DateChangeLast>2017-10-06T06:37:00Z</DateChangeLast><DateAdded>2017-10-03T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Body mass index &gt;/= 18 kg/m2&lt;/li&gt;&lt;li&gt;Aready received bariatric surgery or abdonimal surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Acute stroke or acute myocardial infarction in 6 months&lt;/li&gt;&lt;li&gt;Autoimmune disease&lt;/li&gt;&lt;li&gt;Long-term use of non-steroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Consists with other endocrine diseases&lt;/li&gt;&lt;li&gt;Acute infection in 2  weeks&lt;/li&gt;&lt;li&gt;Cancer&lt;/li&gt;&lt;li&gt;Use of antibiotics in 3 months&lt;/li&gt;&lt;li&gt;Chronic digestive inflammations&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Immunity cells: ratio of immunity cells in circulating and adipose or liver tissue</Description><Timeframe>Up to five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Body weight and height: body weight and height will be combined to report BMI in kg/m2</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Cytokine: cytokines concentrations in circulating and adipose or liver tissue</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Insulin: insulin (mIU/l) concentartions in serum and adipose tissue</Description><Timeframe>Up to five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study focuses on the cause of obesity and impacts of bariatric surgery on it.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects with obesity already received bariatric surgery and healthy subjects with normal body weight and who already received abdominal surgery are enrolled and observed in this study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University</Name><Address1>Nanjing</Address1><Address2>Jiangsu</Address2><Address3>210008</Address3><CountrySubDivision>Jiangsu</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7750">Subjects Scheduled for Bariatric Surgery</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7752">Others</PatientSegment><SubSegments><SubSegment id="18680">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03296605</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20394">Assessment of adipose tissue dynamics</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20464"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20543"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20587"><Endpoint>Assessment of Liver Functions</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20715"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20394">Assessment of adipose tissue dynamics</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20413"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20464"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20524"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20531">Cytokines/Adipokines</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20587"><Endpoint>Assessment of Liver Functions</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint><SubEndpoint disease="Obesity" id="20726">Assessment of height</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion></Inclusion><Inclusion disease="Obesity" id="19743"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19744">Subjects with history/scheduled for bariatric surgery or gastric bypass surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34498"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15293"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15294">Subjects co-morbid with stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15301"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Obesity" id="15309"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Obesity" id="15311"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15331">Subjects with neoplasm/malignancy</SubCriterion><SubCriterion disease="Obesity" id="15332">Subjects co-morbid with inflammatory disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15328"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15350">Subjects with history of/scheduled to receive hormone therapy / steroid / corticosteroid</SubCriterion><SubCriterion disease="Obesity" id="15353">Subjects on prohibited medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="27031"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15323">Subjects co-morbid with myocardial infarction</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2022-03-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-09-12T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-10-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="323812"><TitleDisplay>Chart review study of patients with chronic liver disease taking ayurveda treatment to evaluate the effect on liver functions</TitleDisplay><TitleOfficial>Retrospective, observational, pilot study to evaluate efficacy of herbo-metalic ayurvedic compounds in terms of improving liver functions in patients with chronic liver disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2017/12/010913</Identifier></Identifiers><Indications><Indication id="201">Liver disease</Indication></Indications><BiomarkerNames><BiomarkerName id="10684" role="Disease marker" type="Cellular">Blood cells</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Herbo-metalic ayurvedic formulation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="201" type="ciIndication"><TargetEntity id="10024670" type="MEDDRA"></TargetEntity><TargetEntity id="D008107" type="MeSH"></TargetEntity><TargetEntity id="-35813413" type="omicsDisease"></TargetEntity><TargetEntity id="415" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1158764">Rasayu Cancer Clinic</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>15</PatientCountEnrollment><DateStart>2015-09-30T00:00:00Z</DateStart><DateChangeLast>2018-01-05T09:24:36Z</DateChangeLast><DateAdded>2017-12-27T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Rasayu Clinic</Affiliation><Email>care@rasayucancerclinic.com</Email><Name>DrYogesh Bendale</Name></Contact><Contact type="Public contact"><Affiliation>Rasayu Clinic</Affiliation><Email>avinashk@rbpl.co.in</Email><Name>DrAvinash Kadam</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Chronic liver disease patients &gt; 18 years of age&lt;/li&gt;&lt;li&gt;Who had taken Ayurvedic treatment more than three months (taking Ayurvedic treatment for &gt; 3 months)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who was suffering from any concomitant illness or taking any concomitant medication which in the opinion of investigator would have confounded with outcome efficacy variables&lt;/li&gt;&lt;li&gt;Patient who were receiving other CAM modalities&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes in parameters of liver function test</Description><Timeframe>Monthly</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Changes in Complete Blood count</Description><Timeframe>Monthly</Timeframe></Measure><Measure><Description>Changes in physical symptoms</Description><Timeframe>Monthly</Timeframe></Measure><Measure><Description>QOL</Description><Timeframe>Monthly</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study is to evaluate the efficacy of Herbo-metalic ayurvedic formulations in treating patients with chronic liver failure&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients treated with Herbo-metalic ayurvedic formulations will be observed. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Rasayu Clinic</Name><Address1>Pune</Address1><Address2>MAHARASHTRA</Address2><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18219">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15977">Subjects with Liver Disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="18824">Subjects Scheduled for Specific Procedures</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2017/12/010913</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gastrointestinal disease" id="43414"><Endpoint>Assessment of Liver Functions</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other gastrointestinal disease" id="42974"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43401"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="46262"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35070"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gastrointestinal disease" id="24021"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25170"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25607"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="25183">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><ChangeHistory><Change type="added"><Date>2017-12-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="330233"><TitleDisplay>Comparative Evaluation of Minimally Invasive 'Tibial Tuberoplasty' Surgical Technique Versus Conventional Open Surgery for Tibial Plateau Fractures</TitleDisplay><TitleOfficial>Comparative Evaluation of Minimally Invasive 'Tibial Tuberoplasty' Surgical Technique Versus Conventional Open Surgery for Tibial Plateau Fractures (TUBERIMPACT Study)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03444779</Identifier><Identifier type="Organisational Study">2018-A00168-47</Identifier><Identifier type="Other">2018-A01027-48</Identifier><Identifier type="Trial Acronym">TUBERIMPACT</Identifier></Identifiers><Indications><Indication id="3894">Lower limb fracture</Indication></Indications><BiomarkerNames><BiomarkerName id="46522" role="Therapeutic effect marker" type="Physiological">Knee motion</BiomarkerName><BiomarkerName id="53000" role="Therapeutic effect marker" type="Structural (imaging)">Anterior cruciate ligament</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Tibial Tuberoplasty</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Open technique</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1047446" type="Company"><TargetEntity id="5035544416" type="organizationId">Centre Hospitalier Universitaire Poitiers</TargetEntity></SourceEntity><SourceEntity id="3894" type="ciIndication"><TargetEntity id="10061599" type="MEDDRA"></TargetEntity><TargetEntity id="3341" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1047446">Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>140</PatientCountEnrollment><DateStart>2018-10-26T00:00:00Z</DateStart><DateEnd type="estimated">2021-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-20T07:15:33Z</DateChangeLast><DateAdded>2018-02-27T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>manuel.roulaud@chu-poitiers.fr</Email><Name>Manuel ROULAUD</Name><Phone>+33 549443223</Phone></Contact><Contact type="Scientific contact"><Affiliation>Poitiers Hospital University</Affiliation><Name>Tanguy VENDEUVRE, Dr</Name></Contact><Contact type="Public contact"><Affiliation>Poitiers University Hospital</Affiliation><Email>Veronique.FERRAND-RIGALLAUD@chu-poitiers.fr</Email><Name>Véronique FERRAND-RIGALLAUD</Name><Phone>+33 5 49 44 46 65</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/= 18 years old&lt;/li&gt;&lt;li&gt;Patients with a schatzker type 2 or 3 tibial plateau fracture (compression with or without split) demonstrated on CT-scan and located in the lateral or medial condyle of tibia&lt;/li&gt;&lt;li&gt;Patients with fractures caused by trauma&lt;/li&gt;&lt;li&gt;Patients with fractures&amp;lt; 10 days old&lt;/li&gt;&lt;li&gt;Understand and accept the constraints of the study&lt;/li&gt;&lt;li&gt;Be a beneficiary or affiliated member of a Health Insurance plan&lt;/li&gt;&lt;li&gt;Give written consent for the study after having received clear information&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt; 18 years old&lt;/li&gt;&lt;li&gt;Patients with fractures resulting from osteolysis&lt;/li&gt;&lt;li&gt;Patients with open fractures&lt;/li&gt;&lt;li&gt;Patients with fractures more than 10 days old&lt;/li&gt;&lt;li&gt;Patients with concomitant fracture(s) or condition(s) during the trauma reducing the range of motion&lt;/li&gt;&lt;li&gt;Patients unable to walk before the injury&lt;/li&gt;&lt;li&gt;History of sepsis in the injured knee&lt;/li&gt;&lt;li&gt;Contraindications to anesthesia, contrast agent, medical devices or cement&lt;/li&gt;&lt;li&gt;History of hypersensitivity reactions to contrast media, bone filler or metal&lt;/li&gt;&lt;li&gt;Patients with a degenerative joint disease (polyarthritis, etc,)&lt;/li&gt;&lt;li&gt;Absence of signature of the informed consent form&lt;/li&gt;&lt;li&gt;Patients not covered by French national health insurance&lt;/li&gt;&lt;li&gt;Subjects requiring closer protection, ie, minors, pregnant women, nursing mothers, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patients in an emergency setting&lt;/li&gt;&lt;li&gt;Pregnant women, nursing mothers, women of childbearing potential not using effective contraception (hormonal/barrier: oral, parenteral, percutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Anatomical reduction of tibial plateau fracture: compare step-off anatomical reduction of tibial plateau fracture by 'Tibial Tuberoplasty' versus conventional open surgery using CT-scan</Description><Timeframe>48 h post-operative</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse events</Description><Timeframe>Days 2, 21 and 45, months 3, 6, 12 and 24</Timeframe></Measure><Measure><Description>Knee injury and Osteoarthritis Outcome Score: the KOOS questionnaire is a functional score validated in the French language and one of the only validated in knee trauma. The Knee injury and Osteoarthritis Outcome Score (KOOS) was developed as an extension of the WOMAC Osteoarthritis Index with the purpose of evaluating short-term and long-term symptoms and function in subjects with knee injury and osteoarthritis. The KOOS holds five separately scored subscales: pain, other Symptoms, function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). The KOOS has been validated for several orthopaedic interventions such as anterior cruciate ligament reconstruction, meniscectomy and total knee replacement</Description><Timeframe>Days 2, 21 and 45, months 3, 6, 12 and 24</Timeframe></Measure><Measure><Description>Knee range of motion (degrees)</Description><Timeframe>Days 2, 21 and 45, months 3, 6, 12 and 24</Timeframe></Measure><Measure><Description>Numeric Pain Rating Scale: the NPRS is an 11-point scale from 0 to 10 ('0' = no pain and '10' = the most intense pain imaginable). Patients verbally select a value that is most in line with the intensity of pain that they have experienced in the last 24 h</Description><Timeframe>Days 2, 21 and 45, months 3, 6, 12 and 24</Timeframe></Measure><Measure><Description>Score on Euro Quality of Life-5 Dimension Health questionnaire: the EQ-5D-5L is a standardized instrument used to measure health-related quality of life (HRQoL) which comprises a descriptive system and a visual analogue scale. The descriptive system is composed of 5 questions assessing mobility, self-care, usual activities, pain/discomfort and anxiety/depression with 5 possible responses for each item: 1- no problems, 2- slight problems, 3- moderate problems, 4- severe problems and 5- extreme problems). A global index with a maximum score of 1 is calculated from the responses to these 5 dimensions by means of normograms. The maximum score of 1 indicates the best possible quality of life. The visual analogue scale ranging from 0 to 100 also allows the patient to rate his/her perceived quality of life, where 100 indicates the best possible quality of life</Description><Timeframe>Days 2, 21 and 45, months 3, 6, 12 and 24</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study  is a  larger scale multicenter randomized controlled trial is now requested to further demonstrate the superiority of the 'Tibial Tuberoplasty' to the standard treatment and also designed to evaluate the quality of tibial fracture reduction offered by      percutaneous 'Tibial Tuberoplasty' versus conventional open surgery for tibial plateau      fracture but also its impact on clinical outcome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This randomized study consists of two arms :&lt;br/&gt;Arm 1(Open technique):  patients will be treated with an open technique: cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope. The reduction will be performed using a spatula, a bone tamp or open reduction internal fixation. The osteosynthesis and filling of the cavity will be performed by the same surgical access.&lt;br/&gt;Arm 2(Tibial Tuberoplasty): patients will be treated with the 'Tibial Tuberoplasty' technique under fluoroscopic guidance with or without arthroscopy. The reduction will be performed by an anterior approach using a kyphoplasty balloon. The combined osteosynthesis including cannulated screws and cementoplasty will both be performed by a percutaneous technique.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Poitiers University Hospital</Name><Address1>Poitiers</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Veronique.FERRAND-RIGALLAUD@chu-poitiers.fr</Email><Name>Véronique FERRAND-RIGALLAUD</Name><Phone>+33 5 49 44 46 65</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17553">Subjects Undergoing Surgery</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="19385">Subjects with Bone Injury</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03444779</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="43038"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other musculoskeletal disease" id="42923"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="43042"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46368"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="46369">Pain scores</SubEndpoint><SubEndpoint disease="Other musculoskeletal disease" id="46377">Knee injury and osteoarthritis outcome score(KOOS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46378"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46383"><Endpoint>Assessment of Other Measures of Pain Quality</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46477"><Endpoint>Assessment by Global Assessment Scales</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="46375">Visual analogue scales (VAS) for local and general pain/overall disease activity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="32681"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="34307"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32740">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other musculoskeletal disease" id="34802"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32739">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other musculoskeletal disease" id="35079"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24023"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24089"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24183"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24962"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24043">Pregnant/lactating women</SubCriterion><SubCriterion disease="Other musculoskeletal disease" id="24090">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="25617"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="27918"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-10-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-02-02T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-02-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-10-31T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="365405"><TitleDisplay>E-bikes for individuals with type 2 diabetes</TitleDisplay><TitleOfficial>Promoting electrically-assisted cycling in people with type 2 diabetes: a randomized, pilot study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN67421464</Identifier><Identifier type="Organisational Study">39186</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName><BiomarkerName id="17911" role="Therapeutic effect marker" type="Structural (imaging)">Muscle</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>e-cycling</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1165896" type="Company"><TargetEntity id="5064587378" type="organizationId">National Institute for Health Research Bristol Biomedical Research Centre</TargetEntity></SourceEntity><SourceEntity id="20544" type="Company"><TargetEntity id="4296787325" type="organizationId">University of Bristol</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="20544">University of Bristol</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1165896">NIHR Bristol Biomedical Research Centre</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2018-11-01T00:00:00Z</DateStart><DateEnd type="estimated">2020-01-01T00:00:00Z</DateEnd><DateChangeLast>2019-01-07T10:28:07Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>NIHR Bristol Biomedical Research Centre</Affiliation><Email>jessica.bourne@bristol.ac.uk</Email><Name>Ms Bourne</Name><Phone>+44 (0)117 342 1883/4</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Clinical diagnosis of type 2 diabetes mellitus&lt;/li&gt;&lt;li&gt;Aged 30 to 70 years&lt;/li&gt;&lt;li&gt;Do not currently engage in 150 min of moderate-to-vigorous physical activity per week (assessed by the Get Active Questionnaire; CSEP 2017)&lt;/li&gt;&lt;li&gt;Cleared for engaging in physical activity by their general practitioner&lt;/li&gt;&lt;li&gt;Can read, write and speak English&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Currently taking exogenous insulin&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension (systolic blood pressure [BP]&amp;gt; 160 mmHg and/or diastolic BP &amp;gt; 90 mmHg), for which the individual is not taking medication&lt;/li&gt;&lt;li&gt;Myocardial infarction or stroke within the past six months or evidence of end-stage renal failure or liver disease&lt;/li&gt;&lt;li&gt;Any other contra-indications to exercise&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Recruitment to the trial will be descriptively described</Description><Timeframe>End of the study</Timeframe></Measure><Measure><Description>Willingness of individuals to be randomized will be descriptively described</Description><Timeframe>End of the study</Timeframe></Measure><Measure><Description>Retention rates will be descriptively described</Description><Timeframe>End of the study</Timeframe></Measure><Measure><Description>Adherence to the intervention and research procedure methods including data collection will be measured through calculating the number of individuals who complete each research procedure</Description><Timeframe>End of the study</Timeframe></Measure><Measure><Description>Intervention fidelity will be descriptively described</Description><Timeframe>End of the study</Timeframe></Measure><Measure><Description>Individuals experiences of being part of the trial will be assessed through analysis of data collected through qualitative interviews conducted after post-intervention testing</Description><Timeframe>End of the study</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>BMI and waist circumference measured</Description><Timeframe>At pre and post intervention</Timeframe></Measure><Measure><Description>Barriers and facilitators to e-cycling assessed through qualitative interviews</Description><Timeframe>Post intervention</Timeframe></Measure><Measure><Description>Body composition measured using dual energy X-ray absorptiometry</Description><Timeframe>At pre and post intervention</Timeframe></Measure><Measure><Description>Cardiorespiratory fitness measured using a continuous incremental ramp maximal exercise test</Description><Timeframe>Pre and post intervention</Timeframe></Measure><Measure><Description>E-cycling activity measured using a GPS device</Description><Timeframe>Throughout the intervention</Timeframe></Measure><Measure><Description>Glycated hemoglobin, glucose, insulin, lipids and C-reactive protein and response to an oral glucose tolerance test measured</Description><Timeframe>At pre and post intervention</Timeframe></Measure><Measure><Description>Health-related quality of life measured using the short form SF-36 collected</Description><Timeframe>At pre and post intervention</Timeframe></Measure><Measure><Description>Muscle quality, density and area measured using peripheral quantitative computer tomography</Description><Timeframe>Pre and post intervention</Timeframe></Measure><Measure><Description>Total physical activity measured using accelerometers</Description><Timeframe>Pre and just before the end of the intervention</Timeframe></Measure><Measure><Description>Travel behaviour measured using GPS</Description><Timeframe>Pre and just before the end of the intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objectives for this study are to:&lt;br/&gt;Identify effective methods of recruiting individuals with type 2 diabetes mellitus.&lt;br/&gt;Determine individuals willingness to be randomized.&lt;br/&gt;Determine study retention rates (ie, number of individuals that completed the study) and adherence to the intervention and data collection methods.&lt;br/&gt;Assess intervention fidelity (ie, was the intervention delivered as intended).&lt;br/&gt;Examine the association between the intervention (based on condition allocation) and outcome measures.&lt;br/&gt;Determine standard deviations of outcome measures to inform sample size calculation for a main trial.&lt;br/&gt;Assess experiences of intervention delivery from the perspectives of the instructors to evaluate intervention feasibility and sustainability.&lt;br/&gt;Assess experiences of the intervention from individuals perspectives to understand the acceptability of the intervention and inform further intervention development.&lt;/para&gt;&lt;para&gt;The overarching aims of this study are  to assess the feasibility of an e-bike intervention in individuals with type 2 diabetes mellitus and  to examine the association between the intervention and outcome measures.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A randomized, pilot study will be conducted and will consist of two trial arms: e-biking intervention and waitlist control (no intervention). While the primary aim of this study is to examine feasibility measures, the inclusion of a control group will enable examination of descriptive statistics of the two conditions. In addition, estimates of associations between the intervention and health and travel outcomes will be explored using random-effects linear regression models. Effect estimates will be presented with confidence intervals, but no hypothesis tests will be performed as this is a feasibility study. In addition, this design will be chosen to mirror the design that would be used in a future large-scale, randomized, controlled trial if appropriate.  &lt;/para&gt;&lt;para&gt;Telephone screening prior to entry to the study, the individuals will have a telephone conversation with the chief investigator (CI) to establish eligibility. At this time the CI will ask for the individual's age, sex, physical activity level, diabetes history, medication status and cycling experience and confidence. If it is established that the individual may be eligible for the study he/she will be asked to visit their general practitioner for clearance to participate in the study. The CI will provide the individual with an information letter for the GP and a clearance form to be completed. Once the form has been returned to the researchers (either directly from the surgery or via the individual) the CI will contact the potential individual to arrange a time and date for baseline testing. This will mean the CI has no access to potential individual's personal records without their knowledge. &lt;/para&gt;&lt;para&gt;Baseline testing will occur at two locations. Visit 1 will take place in Clinical Research and Imaging Centre, Bristol. Potential individuals will attend the Clinical Research and Imaging Centre and will arrive fasted. At this time, informed consent will be obtained, and the following assessments will take place: anthropometrics (height, weight, WC), baseline fasting blood tests and frequent sample oral glucose tolerance test. A 2 h after consuming the glucose drink individuals will be given breakfast (granola bar and fruit) and will then be provided with the Actiheart monitor and personal GPS device to wear over the upcoming seven days. Individuals will also be given a 7 days travel diary to complete. This visit will take approximately 180 min.  Visit 2 will take place in &lt;ulink linkType="Company" linkID="20530"&gt;The University of Bath&lt;/ulink&gt;. A 7 days after visit 1 the individual will visit the University of Bath for the following measures; cardiorespiratory fitness and verification, full-body scan, peripheral quantitative computed tomography, food preferences task, the motivation for food reward task and a survey. This visit will take approximately 120 min.  &lt;/para&gt;&lt;para&gt;After the visit, individuals will be randomly assigned to one of two conditions. Randomization will be stratified based on gender and will be performed using computer-generated random numbers by the company sealed envelope (https://www.sealedenvelope.com/). Individuals will be informed of their condition allocation via telephone.  Individuals in the e-bike condition will then commence e-bike training with Life Cycle UK (CREATE center, Bristol). This will consist of up to two one-to-one training sessions. After completion of the training individuals will be loaned an e-bike for 12 weeks. They will be free to take the bike home and ride as they wish.  In week 10 of the e-bike loan period, the CI will provide individuals in all conditions with an activity monitor, personal GPS, and 7 days travel diary for completion over the upcoming 7 days. At the end of this time, the CI will collect the devices and the diary. The e-bikes will be collected from individuals by Life Cycle UK at the end of week 12.  All individuals will commence post testing as soon as possible after the end of the intervention.&lt;/para&gt;&lt;para&gt;During visit 3, Clinical Research and Imaging Center, Bristol Measurements to be taken will include anthropometrics, baseline fasting blood and a frequent sample oral glucose tolerance test. This visit WILL BE expected to take approximately 180 min.  At visit 4, at the University of Bath where the following measures will be taken; cardiorespiratory fitness and verification, full body scan, peripheral quantitative computed tomography, food preferences task, the motivation for food reward task and a survey. This visit will take approximately 120 min.  After this time individuals in the e-bike condition will be invited to participate in a one-to-one interview either face-to-face or on the telephone with the study researcher. This will be expected to take approximately 60 min.  Individuals in the waitlist control will be invited to e-bike training, followed by loaning of the e-bike.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Life Cycle UK</Name><Address1>Bristol</Address1><Address3>BS1 6XN</Address3><Contacts></Contacts></Site><Site><Name>University of Bath</Name><Address1>Claverton Down</Address1><Address3>BA2 7AY</Address3><Contacts></Contacts></Site><Site><Name>University of Bristol (lead centre)</Name><Address1>Bristol</Address1><Address3>BS2 8AE</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN67421464</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1359">Change in HbA1c</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1362"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1423"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1427">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1451"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1502">Assessment of BMI</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1504">Assessment of abdominal circumference</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="33857"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="33864">Assessment by Short Form Health Survey (SF-36)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="45401"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="45701"><Endpoint>Assessment of Neuropsychological Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="697">Subjects able to communicate in the language specified in the protocol</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="1061">Study specific protocol requirements</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="1063">Selection at the discretion of the physician</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34922"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1042">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="831"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="834">Subjects co-morbid with stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="885"><Criterion>Subjects co-morbid with hypertension</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="889">Subjects co-morbid with uncontrolled/untreated hypertension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="957">Subjects on/treated with insulin</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="24931"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="25151"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="26099"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1593">Abnormal vital signs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="28262"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2019-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.00 Months</EnrollmentPeriod><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="379777"><TitleDisplay>Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn´s Disease</TitleDisplay><TitleOfficial>Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn´s Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03941418</Identifier><Identifier type="Organisational Study">UCDRAGISAMISOVIC1</Identifier></Identifiers><Indications><Indication id="337">Ulcerative colitis</Indication><Indication id="84">Crohns disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>standard therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>Saccharomyces boulardii</Name></Intervention><Intervention type="InterventionPrimary"><Name>vitamin D3</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard therapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1075912" type="Company"><TargetEntity id="5037962750" type="organizationId">Klinicki Centar Srbije</TargetEntity></SourceEntity><SourceEntity id="1087502" type="Company"><TargetEntity id="5040242856" type="organizationId">Klinicko-bolnicki centar Dr Dragisa Misovic - Dedinje</TargetEntity></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"></TargetEntity><TargetEntity id="10009900" type="MEDDRA"></TargetEntity><TargetEntity id="D003093" type="MeSH"></TargetEntity><TargetEntity id="-1993209976" type="omicsDisease"></TargetEntity><TargetEntity id="396" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="84" type="ciIndication"><TargetEntity id="K50" type="ICD10"></TargetEntity><TargetEntity id="10011401" type="MEDDRA"></TargetEntity><TargetEntity id="D003424" type="MeSH"></TargetEntity><TargetEntity id="-248155260" type="omicsDisease"></TargetEntity><TargetEntity id="395" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1087502">University Hospital Center Dr Dragisa Misovic</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1075912">Clinical Centre of Serbia, Emergency Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2019-06-01T00:00:00Z</DateStart><DateEnd type="estimated">2020-03-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-30T08:49:10Z</DateChangeLast><DateAdded>2019-05-13T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University Clinic Dr Dragisa Misovic-Dedinje</Affiliation><Email>nikola.panicmail@gmail.com</Email><Name>Nikola Panic, PhD</Name><Phone>+381113630600</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histological diagnosis of ulcerative colitis or Crohn disease&lt;/li&gt;&lt;li&gt;Colonoscopy in last 6 months confirming mild disease form according to endoscopic criteria (Mayo score, simple endoscopic score)&lt;/li&gt;&lt;li&gt;Colonoscopy in last 6 months confirming endoscopic remission with fulfilled clinical Rome IV criteria for irritable bowl syndrome&lt;/li&gt;&lt;li&gt;Patients&lt;/li&gt;&lt;li&gt;Patients with mild disease form are eligible only if treated with mesalazine only&lt;/li&gt;&lt;li&gt;Patients in remission eligible for inclusion if treated with mesalazine, biologics, azathioprine or methotrexate&lt;/li&gt;&lt;li&gt;Signed informed consents&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;No colonoscopy in last 6 months&lt;/li&gt;&lt;li&gt;Moderate to severe disease according to colonosopy findings (Mayo score, simple endoscopic score)&lt;/li&gt;&lt;li&gt;Indeterminate colitis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Patients quality of life: quality of life measured will be measured by questionnaire at day 1, 4 weeks after enrolment and 8 weeks after enrolment. questionnaire comprises 10 questions considering presence of symptoms of inflammatory bowel disease as well as their effect on well-being. Each question can be answered with one of seven answers contributing 1 to 7 points to final score. Final score ranges between 10 and 70 with higher values corresponding with higher quality of life</Description><Timeframe>8 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Disease clinical activity: disease clinical activity will be measured by Mayo score for ulcerative colitis and Harvey-Bardshaw index for Crohn disease at day 1, 4 weeks after enrolment and 8 weeks after enrollment. The Mayo Score evaluates ulcerative colitis activity based on four clinical parameters. Each parameter of the Mayo score ranges from zero (normal or inactive disease) to 3 (severe activity). The Harvey-Bradshaw index for assessing clinical activity in patients with Crohn disease consists of 5 clinical parameters. Calculation formula for both scores considered the sum of the scores of all the parameters included. Higher values of the score are associated with increased clinical activity of the disease</Description><Timeframe>8 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of the study is to assess the impact of treatment with dietary supplement containing      Saccharomyces boulardii (used as an addition to standard therapy), on quality of life of      patients with mild forms of ulcerative colitis and Crohn disease, as well as those in      remission fulfilling criteria for irritable bowel syndrome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients included will be randomly assigned in two groups and subsequently administered with      formulation containing Saccharomyces boulardii or placebo for 4 weeks. &lt;br/&gt;Patient's quality of      life will be assessed by questionnaire at the enrolment and 4 weeks after initiating the      therapy.&lt;/para&gt;&lt;para&gt;Patients will be administered with either a  formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 qd, as an addition to their standard therapy or with placebo of same appearance, colour and taste once daily.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Serbia"><Sites><Site><Name>University Clinic Dr Dragisa Misovic-Dedinje</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Ulcerative colitis</Disease><PatientSegments><PatientSegment><PatientSegment id="8775">Subjects with Mild to Moderate Ulcerative Colitis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8793">Ulcerative Colitis Subjects in Remission</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Crohns disease</Disease><PatientSegments><PatientSegment><PatientSegment id="3405">Subjects with Crohns Disease in Remission</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3753">Subjects with Mild to Moderate Crohns Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03941418</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Crohns disease" id="6407"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Ulcerative colitis" id="15921"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Crohns disease" id="6336"><Endpoint>Crohn's Disease Activity Assessed by Indices/Scores</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6341">Harvey-Bradshaw index (HBI) score</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15898"><Endpoint>Ulcerative Colitis Assessed by Activity Indices</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="15907">Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ulcerative colitis" id="15921"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Ulcerative colitis" id="27837">Harvey bradshw index(HBI)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Crohns disease" id="3163"><Criterion>Subjects with Crohn's Disease in Remission</Criterion></Inclusion><Inclusion disease="Crohns disease" id="3240"><Criterion>Subjects with Abnormal Laboratory Parameters</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3244">Colonoscopy and other imaging indicative of crohn's disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Crohns disease" id="3248"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Crohns disease" id="4344"><Criterion>Subjects with Mild to Moderate Crohn's Disease</Criterion></Inclusion><Inclusion disease="Ulcerative colitis" id="15771"><Criterion>Subjects with Mild to Moderate Ulcerative Colitis </Criterion></Inclusion><Inclusion disease="Ulcerative colitis" id="15777"><Criterion>Subjects in Remission</Criterion></Inclusion><Inclusion disease="Ulcerative colitis" id="15780"><Criterion>Subjects Included Based on Disease Activity Scores</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15781">Subjects enrolled based on Mayo score/disease activity index/MMDAI</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="15826"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15828">Subjects assessed by/indicated for endoscopic examination</SubCriterion><SubCriterion disease="Ulcerative colitis" id="15829">Subjects assessed by/indicated for histologic examination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="15841"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Crohns disease" id="34351"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3249">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ulcerative colitis" id="34407"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="15846">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Crohns disease" id="4403"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4406">Subjects with indeterminate colitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4455"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Crohns disease" id="5689"><Criterion>Subjects with Moderate to Severe Crohn's Disease</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13106"><Criterion>Subjects with Moderate to Severe Ulcerative Colitis</Criterion></Exclusion><Exclusion disease="Ulcerative colitis" id="13120"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13123">Subjects with indeterminate colitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="13142"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13143">Subjects excluded based on endoscopic/histologic findings</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="13166"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Crohns disease" id="27798"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4456">Patient unable or unwilling to comply with protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ulcerative colitis" id="27978"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Ulcerative colitis" id="13167">Patient unable/unwilling to comply with protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-05-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>